Journal Information
Vol. 45. Issue S3.
XIV Eurasian Hematology Oncology Congress
Pages S40 (October 2023)
Share
Share
Download PDF
More article options
Vol. 45. Issue S3.
XIV Eurasian Hematology Oncology Congress
Pages S40 (October 2023)
PP 19
Full text access
LOCALIZED AL AMYLOIDOSIS OF THE URINARY BLADDER PRESENTING WITH PAINLESS MASSIVE HEMATURIA
Visits
322
Kıvanç Koruk1, Murat Özbalak2, Ali Altay3, Gülçin Yeğen3, Sevgi Beşışık Kalayoğlu1
1 Istanbul University Istanbul Medical Faculty, Department of Internal Medicine Division of Hematology, Istanbul Turkey
2 Istanbul University Istanbul Medical Faculty, Department of Pathology Istanbul Turkey
3 Başakşehir Çam ve Sakura City Hospital Department of Internal Medicine Division of Hematology,Istanbul,Turkey
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 45. Issue S3

XIV Eurasian Hematology Oncology Congress

More info
Objective

Amyloid deposits can be localized as a wall thickness or mass lesion either as AA amyloidosis or AL amyloidosis and may develop nearly on all organs. It is generally a mild, non–life-threatening entity with a good prognosis and rarely showed progression to systemic disease

Methodology

We present two cases of urinary bladder localized AL amyloidosis that presents with painless hematuria and imaging studies mimic malignant tumors. Cystoscopic evaluation and biopsy were performed.

Results

63 years male presents with massive hematuria. Ultrasonography revealed a 17 × 14mm mass lesion on the bladder wall. Transurethral biopsy specimen histology showed lambda-type amyloid. The second patient was a 71-year-old male and evaluation for painless hematuria revealed a bladder wall mass lesion whose histology was consistent again with AL amyloidosis. Both patients did not have systemic amyloidosis signs and symptoms

Conclusion

The literature did not include long-term outcomes. Usually, benign nature was depicted, and surgical removal is the preferred treatment. Since the contributing factors are not clear, we are concerned about the risk of recurrence and experienced the challenge of anti-plasma cell therapy giving or not.

Full text is only aviable in PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools